Education
About Us
Working with TipRanks
Follow Us
Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
Total Valuation
Actuate Therapeutics, Inc. has a market cap or net worth of $154.80M. The enterprise value is ―.
Market Cap$154.80M
Enterprise Value―
Share Statistics
Actuate Therapeutics, Inc. has 23,243,328 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,243,328
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Actuate Therapeutics, Inc.’s return on equity (ROE) is -261.89 and return on invested capital (ROIC) is -4876.77%.
Return on Equity (ROE)-261.89
Return on Assets (ROA)-2.93
Return on Invested Capital (ROIC)-4876.77%
Return on Capital Employed (ROCE)-48.77
Revenue Per Employee0.00
Profits Per Employee-2.73M
Employee Count10
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Actuate Therapeutics, Inc. is ―. Actuate Therapeutics, Inc.’s PEG ratio is -0.03.
PE Ratio―
PS Ratio0.00
PB Ratio639.69
Price to Fair Value639.69
Price to FCF-3.05
Price to Operating Cash Flow-6.61
PEG Ratio-0.03
Income Statement
In the last 12 months, Actuate Therapeutics, Inc. had revenue of 0.00 and earned -27.29M in profits. Earnings per share was -3.26.
Revenue0.00
Gross Profit0.00
Operating Income-25.16M
Pretax Income-27.28M
Net Income-27.29M
EBITDA-25.16M
Earnings Per Share (EPS)-3.26
Cash Flow
In the last 12 months, operating cash flow was -20.42M and capital expenditures 2.00, giving a free cash flow of -20.42M billion.
Operating Cash Flow-20.42M
Free Cash Flow-20.42M
Free Cash Flow per Share-0.88
Dividends & Yields
Actuate Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.06
52-Week Price Change-24.34%
50-Day Moving Average6.64
200-Day Moving Average7.58
Relative Strength Index (RSI)47.29
Average Volume (3m)91.29K
Important Dates
Actuate Therapeutics, Inc. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Actuate Therapeutics, Inc. as a current ratio of 1.05, with Debt / Equity ratio of 0.00%
Current Ratio1.05
Quick Ratio1.05
Debt to Market Cap0.00
Net Debt to EBITDA0.33
Interest Coverage Ratio1.34K
Taxes
In the past 12 months, Actuate Therapeutics, Inc. has paid 800.00 in taxes.
Income Tax800.00
Effective Tax Rate>-0.01
Enterprise Valuation
Actuate Therapeutics, Inc. EV to EBITDA ratio is -2.32, with an EV/FCF ratio of -2.67.
EV to Sales0.00
EV to EBITDA-2.32
EV to Free Cash Flow-2.67
EV to Operating Cash Flow-2.67
Balance Sheet
Actuate Therapeutics, Inc. has $16.92M in cash and marketable securities with $0.00 in debt, giving a net cash position of $16.92M billion.
Cash & Marketable Securities$16.92M
Total Debt$0.00
Net Cash$16.92M
Net Cash Per Share$0.73
Tangible Book Value Per Share$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Actuate Therapeutics, Inc. is $22.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$22.50
Price Target Upside246.69% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―